APPOS - Boston

March 4th - March 5th, 2022


Please note: times are subject to change. Please check the syllabus for the most current version of the agenda upon arriving at the summit.

All Times Listed are for the Eastern Standard Time Zone

Friday, March 4, 2022

8:00am Horizon CME App Overview
8:10am Welcome, Introductions, & CE Housekeeping


(01) The Evolution of Drug Therapy in Oncology: Recent Advances in Cancer Drug Therapy
» Valerie Relias, PharmD - Tufts Medical Center
9:15am Break and Exhibitor Announcement
9:35am (02A) Small Cell Lung Cancer: Recent Advances in Therapy
» Catherine B. Meador, MD. PhD - Dana-Farber Cancer Institute
(02B) CAR T-Cell Therapy: Current Status in Oncology
» Caron Jacobson, MD, MMSc Physician - Dana-Farber Cancer Institute 
10:35am Break & Virtual Exhibit Hall | Meet-the-Clinician


(03A) Financial Toxicities and Health Equity Access
» Brenda Lormil, NP MGH -  Massachusetts General Hospital
» Beverly Moy, MD, MPH - Massachusetts General Hospital    

11:55am Break & Virtual Exhibit Hall | Meet-the-Clinician

Non-CME/CE Presentation Sponsored by Pfizer Oncology - Topic: Clinical Trial Evidence for a CDK4/6 Inhibitor Combination Therapy Complemented by an Evaluation of Real-World Effectiveness | Speaker: Christine Helou, MSN, FNP-BC, OCN


(04) Integrating Palliative Care in the Daily Oncology Practice
» Barbara Reville, DNP, ANP-C, ACHPN - Harvard Medical School Center for Palliative Care


(05A) Triple-Negative Metastatic Breast Cancer: Expanding Treatment Beyond Chemotherapy
» V. K. Gadi, MD, PhD - Professor of Medicine and Director of Medical Oncology, University of Illinois at Chicago​​​​​
(05B) New Strategies in Chronic Lymphocytic Leukemia
» Charlene Kabel, PharmD, BCOP - Memorial Sloan Kettering Cancer Center
2:55pm (06) Cancer-Related Thrombosis: The Great Debate on the Best Way to Anticoagulate
» Allison Schepers, PharmD, BCOP - University of Michigan College of Pharmacy
» Danielle Otto, PharmD, BCOP - University of Kentucky Healthcare
4:10pm Closing Comments

Saturday, March 5, 2022

7:10am Non-CME/CE Morning Symposium sponsored by Janssen Oncology: Update on the Treatment of Patients with Multiple Myeloma
» Perry Cook MD;
8:00am Virtual Platform Overview
8:10am Welcome, Introductions, & CE Housekeeping


(07A) Targeting Advanced Renal Cell Carcinoma
» Laura S. Wood RN, MSN, OCN  - Cleveland Clinic Taussig Cancer Center ​​​​​

(07B) Benign Hematology 101: Iron Deficiency Anemia
»Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN - Cleveland Clinic

9:15am Break and Exhibitor Announcements
(08A) Updates and Future Directions in Ovarian Cancer Maintenance Therapy
» Jenny Filipi, NP - Nurse Practitioner Massachusetts General Hospital ​​​

(08B) Managing Patients with Relapsed/Refractory Multiple Myeloma: An Update on Emerging Strategies
» Shahrier Hossain, PharmD  - Clinical Pharmacy Specialist Dana Farber Cancer Institute

10:35am Break & Virtual Exhibit Hall | Meet-the-Clinician


(09) Compassion Fatigue & Provider Burnout: How Can Self-Care Strategies Enhance Provider Well-Being?
» Justin Baker, MD - St Jude Children's Research Hospital

11:55am Break & Virtual Exhibit Hall | Meet-the-Clinician
12:10pm Non-CME/CE Presentation Sponsored by Incyte: : PEMAZYRE® (pemigatinib): The First FDA-Approved Treatment for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma (CCA) with an FGFR2 Fusion or Rearrangement
» Gabriel Schwartz, MSN, FNP-BC, AOCNP
12:55pm (10) Symptom Management in Oncology: Helping Patients Improve Their Quality of Life
» Kathy Chuang, MD MGH 
» Michael L. Dougan, MD, PhD


(11A) Esophageal and Gastroesophageal Junction Cancers: Strategies in Treatment and Management
» Matthew Strickland, MD - Dana Farber Cancer Institute​​​​​

(11B) Managing Diffuse Large B-cell Lymphoma in 2022: Novel Therapeutic Strategies in the Relapsed/Refractory Setting
» Kaitlen Reyes, FNP, DNP - Dana Farber Cancer Institute 

2:55pm Closing Comments